Long-term efficacy and safety of antitumour necrosis factor alpha treatment in rhupus: an open-label study of 15 patientsFrançois Danion, Christelle Sordet, L. Sparsa et al.|RMD Open|2017Cited by 29
Brief Report: Spatial Heterogeneity of Systemic Sclerosis in France: High Prevalence in the Northeast RegionAlain Meyer, Jean Sibilia, Emmanuel Chatelus et al.|Arthritis & Rheumatology|2016Cited by 24
Incidence and predictors of COVID-19 and flares in patients with rare autoimmune diseases: a systematic survey and serological study at a national reference center in FranceRenaud Felten, Laurent Arnaud, Marc Scherlinger et al.|Arthritis Research & Therapy|2021Cited by 15
Tolerance and efficacy of targeted therapies prescribed for off-label indications in refractory systemic autoimmune diseases: data of the first 100 patients enrolled in the TATA registry (TArgeted Therapy in Autoimmune Diseases)Jacques‐Eric Gottenberg, Xavier Mariette, Aurore Chaudier et al.|RMD Open|2022Cited by 4
Tolérance et efficacité des thérapies ciblées prescrites pour des indications hors AMM dans les maladies auto-immunes systémiques réfractaires : données des 187 premiers patients inclus dans le registre TATA (TArgeted Therapy in Autoimmune Diseases)Jacques‐Eric Gottenberg, X. Mariette, Baïdy Sy Kane et al.|Revue du Rhumatisme|2023Cited by 0